Kymera Therapeutics Revenue and Competitors
Estimated Revenue & Valuation
- Kymera Therapeutics's estimated annual revenue is currently $25.6M per year.
- Kymera Therapeutics's estimated revenue per employee is $125,985
- Kymera Therapeutics's total funding is $454M.
Employee Data
- Kymera Therapeutics has 203 Employees.
- Kymera Therapeutics grew their employee count by 27% last year.
Kymera Therapeutics's People
| Name | Title | Email/Phone |
|---|---|---|
1 | Founder, President and CEO | Reveal Email/Phone |
2 | Chief Financial Officer | Reveal Email/Phone |
3 | VP | Reveal Email/Phone |
4 | Head Strategic Sourcing | Reveal Email/Phone |
5 | SVP, Information Technology and Operations | Reveal Email/Phone |
6 | VP Finance | Reveal Email/Phone |
7 | VP Preclinical Development | Reveal Email/Phone |
8 | VP, People + Culture | Reveal Email/Phone |
9 | VP, Head Business Development | Reveal Email/Phone |
10 | SVP, Head Research | Reveal Email/Phone |
Kymera Therapeutics Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $5.2M | 67 | -45% | $107.3M | N/A |
#2 | $0.3M | 2 | 0% | N/A | N/A |
#3 | $5.1M | 33 | 6% | N/A | N/A |
#4 | $11.9M | 77 | -37% | $312.8M | N/A |
#5 | $0.9M | 6 | 0% | N/A | N/A |
#6 | $235M | 300 | -5% | $340.9M | N/A |
#7 | $45.9M | 237 | -7% | $7.6M | N/A |
#8 | $3.9M | 50 | 35% | N/A | N/A |
#9 | $5.4M | 35 | 3% | N/A | N/A |
#10 | $1.6M | 10 | 0% | N/A | N/A |
What Is Kymera Therapeutics?
Kymera Therapeutics is pioneering a transformative new approach to treating previously untreatable diseases. We are advancing the field of targeted protein degradation, accessing the body's innate protein recycling machinery to degrade rather than inhibit dysregulated, disease-causing proteins. Powered by a proprietary predictive modeling capability and a game-changing integrated degradation platform with a novel small molecule modality, our company is committed to accelerating drug discovery with an unmatched ability to target and degrade the most intractable of proteins, and advance new treatment options for patients. Learn more at kymeratx.com.
keywords:N/A
$454M
Total Funding
203
Number of Employees
$25.6M
Revenue (est)
27%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Kymera Therapeutics News
Kymera Therapeutics, Inc, a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively...
Shareholders in Kymera Therapeutics (NASDAQ:KYMR) have lost 11%, as stock drops 8.8% this past week. By: Simply Wall St. Published: April 22,...
WATERTOWN, Mass., April 08, 2022 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company...
Kymera Therapeutics Inc., a biotechnology company pioneering targeted protein degradation to invent breakthrough protein degrader medicines for patients, today announced the closing of a $102 million Series C financing. The round was led by Biotechnology Value Fund (BVF) and Redmile Group with p ...
Kymera Therapeutics Inc., a Cambridge, Mass.-based biotechnology company pioneering targeted protein degradation to invent breakthrough protein degrader medicines for patients, closed a $102m Series C financing. The round was led by Biotechnology Value Fund (BVF) and Redmile Group with particip ...
Other Companies in Cambridge
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $51M | 203 | 5% | N/A |
#2 | $31.6M | 204 | 6% | N/A |
#3 | $49.6M | 205 | 10% | N/A |
#4 | $32M | 205 | -13% | $3.2M |
#5 | $31.3M | 208 | -34% | $1.9B |